We serve Chemical Name:Heraclenin CAS:2880-49-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Heraclenin
CAS.NO:2880-49-1
Synonyms:7H-Furo[3,2-g][1]benzopyran-7-one, 9-[(3,3-dimethyloxiranyl)methoxy]-;9-[(3,3-Dimethyl-2-oxiranyl)methoxy]-7H-furo[3,2-g]chromen-7-one;9-[(3,3-dimethyloxiran-2-yl)methoxy]-7H-furo[3,2-g]chromen-7-one;7H-Furo(3,2-g)(1)benzopyran-7-one, 9-(2,3-epoxy-3-methylbutoxy)-, (R)-(+)-
Molecular Formula:C16H14O5
Molecular Weight:286.279
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:471.4±45.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.606
PSA:65.11000
Exact Mass:286.084137
LogP:1.67
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 7H-Furo[3,2-g][1]benzopyran-7-one, 9-[(3,3-dimethyloxiranyl)methoxy]- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7H-Furo(3,2-g)(1)benzopyran-7-one, 9-(2,3-epoxy-3-methylbutoxy)-, (R)-(+)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7H-Furo[3,2-g][1]benzopyran-7-one, 9-[(3,3-dimethyloxiranyl)methoxy]- Use and application,9-[(3,3-dimethyloxiran-2-yl)methoxy]-7H-furo[3,2-g]chromen-7-one technical grade,usp/ep/jp grade.
Related News: Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. Heraclenin manufacturer In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. Heraclenin supplier Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. Heraclenin vendor A number of factors influenced the decision by the U.S. Centers for Disease Control and Prevention, including the COVID-19 pandemic, too few facilities to quarantine dogs safely and three recent incidents where rabies-infected dogs were brought into the country, CNN reported. Heraclenin factory Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost.
